ABSTRACT The CTN-0110 MURB study is a 12-week randomized, double-blind, placebo-controlled Phase IIb trial that will investigate the use of injectable buprenorphine (BUP-Inj) compared to injectable placebo (PBO-Inj) for the treatment of methamphetamine use disorder (MUD) among individuals with mild co-use of opioids or opioid misuse not warranting medication for opioid use disorder (MOUD). Participants will complete all study-related tasks over a period of 19 weeks (up to 3 weeks for screening, 12 weeks for the medication phase, and a follow-up safety visit at Week 16).The study intervention is 3 doses of 300mg BUP-Inj (or PBO-Inj) delivered by abdominal subcutaneous injection at Weeks 1, 5 and 9. The primary objective is to evaluate whether assignment to 12 weeks of outpatient BUP-Inj compared to 12 weeks of outpatient PBO-Inj reduces methamphetamine (MA) use as measured by twice-weekly urine drug screens (UDS) during Weeks 9-12. For the primary statistical analysis, generalized estimating equations will be used to model the log-odds of a MA- negative UDS during Weeks 9-12, assuming an autoregressive lag-1 working correlation matrix. The robust (sandwich) estimator will be used to adjust the covariances for the correlation of UDS from the same participant. Missing UDS are imputed as MA-positive.